Newsbenzinga
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine
· Published
Article summary
Merck reports Phase 2b/3 BRUNELLO trial data for remigromig in DME, achieving vision non-inferiority to ranibizumab alongside elevated adverse event rates.
An excerpt from the original article.
Comments —
Loading comments…